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Although sexual maturation during puberty and mature reproductive function are dependent primarily upon gonadal stimulation by pituitary secretion of LH and FSH, in vitro studies show that growth hormone (GH) and insulin-like growth factor I (IGF-I) may influence gonadal function, particularly in a paracrine and/or autocrine fashion (1) . The testis is a site of IGF-I synthesis (1) under regulation by both GH (2, 3) and gonadotrophins (1) . Testicular receptors for GH (4) and IGF-I (5, 6) have been demonstrated and intratesticular IGF-I may exert a paracrine role in regulating Leydig cell function (1) and spermatogenesis (7, 8) . In contrast, an in vivo role of GH and IGF-I in augmenting gonadotrophin-dependent testicular steroidogenesis or spermatogenesis remains less clearly established (8) . Evidence such as delayed puberty in children with GH deficiency (9) , impaired gonadal function in GHdeficient adults (10, 11) and reduced seminal plasma IGF-I concentrations in azoospermic men (12) indicate the potential importance of the GH/IGF-I axis but direct »Presented in part at the Serono Symposium "GHRH, GH and IGF-I: Basic clinical studies examining a role for GH in gonado¬ trophin stimulation of the human testis have been controlled inadequately owing to ethical and practical constraints on human experimentation (13) (14) (15) (16) . In seasonal breeders, including rhesus macaques, cyclic changes in testis size and spermatogenesis (17) can confound treatment effects under observation. The relatively large body size of baboons makes physiologi¬ cal studies technically easier to perform and even in (Table 2) At entry into the study, the prepubertal male baboon pairs were closely matched for body weight although the ages ranged from 1.8 to 3.0 years. All had low (8) . Alternative explanations for our negative findings, including inadequate study power, insufficient GH and/or IGF-I doses and the prepubertal, non-GH-deficient status of the monkeys, are considered unlikely to invalidate this conclusion. The serial cross¬ over study design was efficient to minimize usage of non-human primates. By rotating baboons through each treatment (rhGH, rhIGF-I or saline), each animal underwent all six combinations of stimuli, thus minimizing the effects of between-animal variability while providing internal control for time-related changes in environmental and other unidentified potentially confounding variables. For these reasons, this design has greater power than the comparable parallel group design with six groups of six monkeys (18) .
The doses used in this study were based on those used clinically in non-GH-deficient humans (29, 30) and could be expected to achieve adequate circulating hormone levels. Although circulating IGF-I levels 24 h after the last dose remained elevated after rhGH, they had returned to baseline 24 h after the last rhIGF-I dose.
This contrasts with a similar human study where the same IGF-I dose produced total and free IGF-I levels that remained elevated above baseline 24 (36) in rats (37) and humans (34) but not in rams (38) . The (1) . Similarly, the inability of rhGH and rhIGF-I to alter FSH-induced inhibin secretion is consistent with a previous in vitro study in rat Sertoli cells (41) but not in granulosa cell cultures (42) . Our (14, 15) . One recent study reported increased sperm density and serum testosterone in gonadotrophin-deficient men who had rhGH treatment added to continuing gonadotrophin regimes (14) . The lack of concurrent non-GH-treated controls makes it impossible to exclude the alternative explanation that the observed effect was due to continued gonadotrophin treatment, which has char¬ acteristically slow effects (43) , rather than to GH administration. Another study demonstrated a modest reduction in hCG-stimulated testosterone secretion following cessation of rhGH therapy in four males with multiple pituitary hormone deficiency (15 
